Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Update

Bluejay Diagnostics, Inc. (NASDAQ:BJDXGet Free Report) saw a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 25,685 shares, a growth of 57.9% from the January 15th total of 16,265 shares. Currently, 3.6% of the company’s shares are short sold. Based on an average trading volume of 166,115 shares, the days-to-cover ratio is presently 0.2 days. Based on an average trading volume of 166,115 shares, the days-to-cover ratio is presently 0.2 days. Currently, 3.6% of the company’s shares are short sold.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Bluejay Diagnostics to a “sell” rating in a report on Saturday, November 1st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Get Our Latest Research Report on Bluejay Diagnostics

Bluejay Diagnostics Price Performance

BJDX opened at $2.67 on Friday. Bluejay Diagnostics has a one year low of $2.51 and a one year high of $40.80. The business has a 50 day simple moving average of $3.15 and a two-hundred day simple moving average of $5.50. The firm has a market capitalization of $1.90 million, a price-to-earnings ratio of -0.01 and a beta of 0.67.

About Bluejay Diagnostics

(Get Free Report)

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.

Recommended Stories

Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.